These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9716065)

  • 21. New kinds of treatment.
    AIDS Treat News; 2001 Jan; (377):4-5. PubMed ID: 11862809
    [No Abstract]   [Full Text] [Related]  

  • 22. GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
    Petrova EE; Simonova MA; Komaleva RL; Britsina MV; Andronova TM; Nesmeyanov VA; Valyakina TI
    Biomed Pharmacother; 2010 Apr; 64(4):240-8. PubMed ID: 19932583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
    Ivanov VT; Andronova TM; Nesmeianov VA; Pinegin BV; Ledger P; Bomford R; Khaitov RM
    Klin Med (Mosk); 1997; 75(3):11-5. PubMed ID: 9229604
    [No Abstract]   [Full Text] [Related]  

  • 24. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.
    Bahr GM
    J Antimicrob Chemother; 2003 Jan; 51(1):5-8. PubMed ID: 12493780
    [No Abstract]   [Full Text] [Related]  

  • 25. [The characteristics of the action of a chemical immunomodulator in a latent viral infection].
    Kalenderov AK; Semenova IB
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):87-8. PubMed ID: 8079590
    [No Abstract]   [Full Text] [Related]  

  • 26. [The principles in correcting secondary immunodeficiencies by using 2 immunomodulators of differing character--purified staphylococcal anatoxin and likopid].
    Semenova IB
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):100-4. PubMed ID: 9532703
    [No Abstract]   [Full Text] [Related]  

  • 27. Liposome-enhanced tumour therapy in canine mammary gland tumours.
    Teske E; Rutteman GR
    Tijdschr Diergeneeskd; 1993 Mar; 118 Suppl 1():32S-33S. PubMed ID: 8480312
    [No Abstract]   [Full Text] [Related]  

  • 28. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1991; 12():193-212. PubMed ID: 1931443
    [No Abstract]   [Full Text] [Related]  

  • 29. [Enhancement of resistance to microbial infection].
    Tamura M; Mameoka Y; Tsubura E
    Nihon Kyobu Shikkan Gakkai Zasshi; 1985 Feb; 23(2):171-5. PubMed ID: 3839543
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase I study and clinical pharmacological study of muroctasin.
    Ichihara N; Kanazawa R; Sasaki S; Ono K; Otani T; Yamaguchi F; Une T
    Arzneimittelforschung; 1988 Jul; 38(7A):1043-69. PubMed ID: 3263868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvants of immunity.
    Chedid L
    Ann Inst Pasteur Immunol (1985); 1985; 136D(3):283-91. PubMed ID: 3913381
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical tolerance and profile of cytokine induction in healthy volunteers following the simultaneous administration of ifn-alpha and the synthetic immunomodulator murabutide.
    Darcissac EC; Vidal V; Guillaume M; Thebault JJ; Bahr GM
    J Interferon Cytokine Res; 2001 Sep; 21(9):655-61. PubMed ID: 11576459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of muramyl dipeptide analog, GMPD, incorporated into liposomes of various composition on the functional activity of macrophages].
    Stefanov AV; Bondar' OP; Umanskiĭ VIu; Lishko VK; Baletskiĭ KP
    Ukr Biokhim Zh (1978); 1989; 61(6):63-9. PubMed ID: 2561033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.
    Bahr GM; De La Tribonniere X; Darcissac E; Ajana F; Bocket L; Sissoko D; Yazdanpanah Y; Dewulf J; Amiel C; Mouton Y
    J Antimicrob Chemother; 2003 Jun; 51(6):1377-88. PubMed ID: 12716777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of the immunomodulator glucosaminylmuramyl dipeptide on hematopoiesis in mice with experimental cytopenia].
    Andrianova IE; Filimonova GI; Andronova TM
    Radiobiologiia; 1992; 32(4):566-70. PubMed ID: 1410295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Synthesis and protective anti-infective action of anomeric lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine].
    Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
    Bioorg Khim; 2006; 32(4):424-31. PubMed ID: 16909867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
    Akhmatova NK; Semenova IB; Donenko FV; Kiselevskiĭ MV; Kurbatova EA; Egorova NB
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (6):35-40. PubMed ID: 17163136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative characteristic of the treatment efficacy in patients with often recurrent acute respiratory infections complicated with immunodeficiency treated with likopid].
    Chop'iak VV; Pot'omkina HO
    Lik Sprava; 2013 Mar; (2):106-17. PubMed ID: 24605620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of GMDP encapsulated into liposomes on metastatic spread of Lewis lung carcinoma].
    Umanskiĭ VIu; Stefanov AV; Bondar' OP; Braginskiĭ SA; Balitskiĭ KP
    Eksp Onkol; 1988; 10(5):40-3. PubMed ID: 2850149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in purine metabolism in the macrophages of mice exposed to a new synthetic analog of muramyl dipeptide].
    Umanskiĭ VIu; Tarakhovskiĭ AM; Andronova TM
    Biull Eksp Biol Med; 1985 Jun; 99(6):685-7. PubMed ID: 2990603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.